Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1124901

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Nusinersen
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what discussions they have had with (1) NICE, (2) NHS England, and (3) Biogen, on a Managed Access Agreement for Spinal Muscular Atrophy treatment, Spinraza.
tabling member printed	Baroness Thomas of Winchester
uin	HL15576
answer	answer is ministerial correction date of answer 17/05/2019 answer text <p>Departmental officials are in regular contact with colleagues in the National Institute for Health and Care Excellence (NICE) and NHS England about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen). Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting and NICE is now able to recommend the use of Spinraza for National Health Service patients in England, subject to a managed access agreement agreed between NHS England and Biogen. The final appraisal document will be published in due course.</p><p> </p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL15577 question first answered 17/05/2019 11:07:46 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	3785 label Biography information for Baroness Thomas of Winchester

1124902

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Institute for Health and Care Excellence
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government when they estimate that NICE will publish the outcome of the NICE Evaluation Committee meeting held on 6 March.
tabling member printed	Baroness Thomas of Winchester
uin	HL15577
answer	answer is ministerial correction date of answer 17/05/2019 answer text <p>Departmental officials are in regular contact with colleagues in the National Institute for Health and Care Excellence (NICE) and NHS England about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen). Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting and NICE is now able to recommend the use of Spinraza for National Health Service patients in England, subject to a managed access agreement agreed between NHS England and Biogen. The final appraisal document will be published in due course.</p><p> </p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL15576 question first answered 17/05/2019 11:07:46 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	3785 label Biography information for Baroness Thomas of Winchester

1124924

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ophthalmic Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 March 2019 to Question 231467 on Ophthalmic Services, whether he has made an assessment of the ability for clinicians to take into account patients’ wishes for concomitant treatment in relation to potential restrictions of the 2019/2020 NHS Tariff.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	251327
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>For the 2017/19 national tariff (which was set for two years), the prices for BZ91 were manually increased above the initially modelled level (based on 2014/15 reference costs) following feedback from the ophthalmology Expert Working Group (EWG). For 2019/20, the EWG recommended that the prices for BZ91 should not be increased and should remain as modelled (based on 2016/17 reference costs).</p><p>The EWG also confirmed that minimally invasive glaucoma surgery (MIGS) and cataract activity are commonly done together and it would not usually be in the patient’s best interest to do them separately. The EWG advised that BZ91 was appropriate for combined MIGS and cataract activity – a MIGS procedure plus a cataract procedure should not receive over twice as much as either procedure alone.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 15/05/2019 16:43:32 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1124974

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Phenylketonuria: Sapropterin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the NICE appraisal of Kuvan will consider the increased prevalence of neuropsychiatric comorbidities in adults with phenylketonuria.
tabling member constituency	Birmingham, Edgbaston
tabling member printed	Preet Kaur Gill
uin	251357
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>In developing its recommendations on Kuvan, the National Institute for Health and Care Excellence (NICE) will consider all the health-related costs and benefits associated with the treatment in accordance with its published methods and processes and the scope for the appraisal that has been developed in consultation with stakeholders; potentially including any costs from National Health Service funded treatments that can be avoided such as food supplements. The NICE appraisal of Kuvan is now underway and NICE expects to publish final guidance next year.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251358 question first answered 15/05/2019 16:31:51 answering member 4455 label Biography information for Seema Kennedy
tabling member	4603 label Biography information for Preet Kaur Gill

1124975

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sapropterin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 November 2018 to Question 190518 on Sapropterin, whether the NICE appraisal of Kuvan will take into account the costs from NHS funded treatments that can be avoided such as food supplements.
tabling member constituency	Birmingham, Edgbaston
tabling member printed	Preet Kaur Gill
uin	251358
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>In developing its recommendations on Kuvan, the National Institute for Health and Care Excellence (NICE) will consider all the health-related costs and benefits associated with the treatment in accordance with its published methods and processes and the scope for the appraisal that has been developed in consultation with stakeholders; potentially including any costs from National Health Service funded treatments that can be avoided such as food supplements. The NICE appraisal of Kuvan is now underway and NICE expects to publish final guidance next year.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251357 question first answered 15/05/2019 16:31:51 answering member 4455 label Biography information for Seema Kennedy
tabling member	4603 label Biography information for Preet Kaur Gill

1125045

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pregnancy: Mental Illness
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of (a) identification and (b) treatment of perinatal mental illnesses; and if he will make a statement.
tabling member constituency	Brighton, Pavilion
tabling member printed	Caroline Lucas
uin	251267
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>The Department is committed to improving both the detection and treatment of perinatal mental illness.</p><p> </p><p>The Five Year Forward View for Mental Health committed to invest £365 million from 2015/16 to 2020/21 in perinatal mental health services to ensure that by 2020/21 at least 30,000 more women each year are able to access evidence-based specialist mental health care during the perinatal period.</p><p> </p><p>The NHS Long Term Plan, published in January 2019, includes a commitment for a further 24,000 women to be able to access specialist perinatal mental health care by 2023/24. Specialist care will also be available from preconception to 24 months after birth, which will provide an extra year of support. Support will also be extended to fathers and partners of women accessing specialist perinatal mental health services and maternity outreach clinics.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 15/05/2019 16:38:49 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	3930 label Biography information for Caroline Lucas

1125053

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pregnancy: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what his Department's timetable is for the national roll-out of non-invasive prenatal testing, as recommended by the UK National Screening Committee in November 2016.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	251394
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>The procurement for providers to undertake the evaluative roll out of non-invasive prenatal testing (NIPT) in England is currently being undertaken on behalf of Public Health England by NHS England as part of the Genomic Testing Services procurement.</p><p>There has been a legal challenge which relates only to the NIPT element of the current procurement which means that there is currently an automatic suspension in place. The extent of the delay will depend on how the litigation proceeds.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 15/05/2019 16:37:43 answering member 4455 label Biography information for Seema Kennedy
tabling member	4249 label Biography information for Anne Marie Morris

1125119

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Health Services: Birkenhead
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will review the (a) causes of, (b) prevention measures for and (c) relief available for (i) depression and (ii) poor mental health in Birkenhead.
tabling member constituency	Birkenhead
tabling member printed	Frank Field
uin	251248
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>Clinical commissioning groups are responsible for ensuring adequate provision and access to mental health services for their local populations and keeping services under review.</p><p>The local Primary Care Network, including mental health services, is working in close collaboration with primary care and wider health and care organisations to specifically target areas of need.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 15/05/2019 16:32:34 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	478 label Biography information for Lord Field of Birkenhead